The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...